GRAL

GRAIL is a single-product, commercial-stage company whose entire equity value rests on Galleri, a multi-cancer blood test that the company itself states 'is not currently broadly reimbursed.' That one sentence in the MD&A is the whole thesis: $147M of FY2025 revenue (+17.2%) is being generated largely out-of-pocket and through discounts/rebates that management explicitly expects to 'reduce our ASP over time.' Against that thin, low-quality revenue the company posted a -$562M operating loss (operating margin -382%) and burned -$299M in operating cash. With only $250M of cash on hand, that is roughly a single year of runway from cash alone; shares already grew 21% in FY2025, so further dilution to fund the burn is the base case, not the risk case. The headline 'net loss improved 80% to -$408M' is misleading — prior years (-$1.47B, -$2.03B) were inflated by acquisition/impairment charges from the Illumina pushdown accounting, so the improvement reflects fewer writedowns, not a path to profitability.

The balance sheet looks deceptively clean — equity of $2.58B and liabilities/equity of just 0.13x — but the $2.92B asset base is dominated by intangibles (developed-technology and IPR&D measured at fair value at the Acquisition, amortized over 18 years), not productive cash-generating assets. Stripping those, the company's tangible cushion is the $954M of current assets against a relentless cash outflow. Two structural headwinds compound this: the Restructuring Plan has cut R&D 39% and abandoned the DAC pipeline, narrowing the company to a one-test bet, and royalties under the Illumina Supply Agreement begin December 24, 2026, which management concedes will 'at least partially offset' any scale-driven margin gains — i.e., a cost step-up arrives just as the company needs margins to improve.